Analyst
Leerink Partners
Equibles does not estimate personal net worth.
Roana Ruiz is recorded as Analyst at Leerink Partners. Roana Ruiz has spoken on 7 earnings calls across 5 companies, most recently for Trevi Therapeutics, Inc. on August 6, 2026. Those appearances were for Trevi Therapeutics, Inc. (TRVI), Cytokinetics Inc (CYTK), Lexicon Pharmaceuticals, Inc. (LXRX), Vir Biotechnology, Inc. (VIR) and Ardelyx, Inc. (ARDX). The companies whose calls Roana Ruiz spoke on are classified in the Healthcare sector.
“I was curious about the upcoming meeting with the FDA on ILD chronic cough, and what questions do you expect to get from the agency?”
“So, I was curious regarding the different metrics that you're tracking for my course's U.S. launch, just the big picture, are there any that seem to be accelerating more than others into the quarter?”
“I wanted to ask a question about Sonata. and if you're able to share the proportion of patients on CMIs and how you think that might impact both the overall results and informing future prescribing, because I noticed that you're talking about majority of patients are NHCM.”
“So with the enrollment completed for Eclipse 2, can you talk a bit about what thresholds you're hoping to see on both efficacy and safety from that particular study and how the data on switching from Believer Tide could help inform future physician prescribing?”
“First one, I was curious, what are your goals for the upcoming meeting with the FDA to talk about the protocol for your Phase IIb and non-IPF ILD chronic coughs, and if you could elaborate, like, anything you expect that might be up for discussion with the FDA versus more straightforward questions?”
Leerink Partners
Analyst
Transcript header (unverified)
CYTK
Biotechnology · Healthcare
ARDX
Biotechnology · Healthcare
